GlobeNewswire

Primary endpoint achieved with ziritaxestat  in NOVESA trial in systemic sclerosis patients

Share

Mechelen, Belgium; 11 September 2020, 04.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) reports positive topline results in the NOVESA Phase 2a clinical trial with investigational ziritaxestat (GLPG1690) in patients with diffuse cutaneous systemic sclerosis (dcSSc).

Ziritaxestat reached the primary endpoint of the study with a statistically significant change from baseline in the modified Rodnan Skin Score (mRSS) at Week 24, of -8.3 vs -5.7 for placebo.   

600 mg ziritaxestat,
n=21
placebo,
n=12
Mean baseline mRSS (standard deviation) 27.0 (8.8) 22.5 (6.2)
Mean change from baseline (standard error) at Week 24, p-value1 -8.3 (1.2), p=0.0411 -5.7 (1.7)

NOVESA is a double-blind, placebo-controlled Phase 2a proof-of-concept trial evaluating the efficacy, safety and tolerability of ziritaxestat (GLPG1690) in 33 patients with dcSSc. DcSSc is a severe autoimmune disease with one of the highest mortality rates among rheumatic diseases2 with no drugs currently approved to treat the overall disease. Systemic sclerosis (SSc) affects approximately 124,000 people3 in the US and Europe4, with a predominance of female patients (>80%).

Patients recruited for NOVESA included mostly females (70%) around 50 years old, with a mean disease duration of 1.9 years. Most patients enrolled were on a background immunosuppressant therapy during the course of the study.

Ziritaxestat was generally well tolerated. No deaths were reported in this study. Two patients taking ziritaxestat experienced serious adverse events versus one patient in the placebo group. Both patients in the ziritaxestat group recovered fully and are still participating in the long-term extension trial.

94% of patients (31 of the 33) who completed the NOVESA trial continued in the long-term open label extension trial.

“We are excited to see that after showing promising activity in the phase 2 FLORA trial in idiopathic pulmonary fibrosis, ziritaxestat achieved statistically significant improvements in mRSS in diffuse SSc, the primary endpoint in the NOVESA study. Keeping in mind that this is our first study in SSc and that the impact on skin is difficult to measure on a background treatment with immunosuppressants, we are pleased with the results reported today. We will now further analyze the NOVESA data to determine next steps in SSc, a disease with important unmet medical need,” said Dr Walid Abi-Saab, Chief Medical Officer of Galapagos.

Detailed results from the NOVESA trial will be presented at future medical conferences.

Ziritaxestat is an investigational drug and not approved by any regulatory authority. Its efficacy and safety have not been established.

About ziritaxestat
Ziritaxestat is a small molecule, selective autotaxin inhibitor co-developed with Gilead Sciences, Inc. as part of the global collaboration between Galapagos & Gilead. Autotaxin is the main enzyme responsible for lysophosphatidic acid (LPA) production. LPA is a well-known pro-fibrotic and pro-inflammatory lipid, acting through at least 6 g-protein coupled receptors. Galapagos identified the autotaxin target using its proprietary target discovery platform and developed molecule ziritaxestat as an inhibitor of this target. Ziritaxestat has orphan drug designation from the US and EU in both idiopathic pulmonary fibrosis (IPF) and SSc and is currently being studied in a global Phase 3 program in IPF (ISABELA), in addition to the ongoing NOVESA extension trial.  

For more information about ziritaxestat: www.glpg.com/glpg-1690
For information about the studies with ziritaxestat in systemic sclerosis: www.clinicaltrials.gov

About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Contacts

Investors:
Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784

Sofie Van Gijsel
Senior Director Investor Relations
+32 485 191415
ir@glpg.com

Media:
Carmen Vroonen
Global Head Communications & Public Affairs
+32 473 824 874

Anna Gibbins
Senior Director Therapeutic Areas Communications
+44 7717 801900
communications@glpg.com

Forward-looking statements

This release may contain forward-looking statements, including, among other things, statements regarding Galapagos' strategic ambitions, the mechanism of action and potential activity of ziritaxestat the anticipated timing of clinical trials with ziritaxestat, the progression and results of such trials, future regulatory submissions and Galapagos' interactions with regulatory authorities. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos’ results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are thatGalapagos’ expectations regarding its ziritaxestat development program may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from Galapagos’ ongoing clinical research programs may not support registration or further development of ziritaxestat due to safety, efficacy or other reasons), Galapagos’ reliance on collaborations with third parties (including its collaboration partner for ziritaxestat, Gilead), and estimating the commercial potential of ziritaxestat. A further list and description of these risks, uncertainties and other risks can be found in Galapagos’ Securities and Exchange Commission (SEC) filings and reports, including in Galapagos’ most recent annual report on Form 20-F filed with the SEC and other filings and reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.



1 P-value calculated based on least square means

2 Nikpour et al. Curr Opin Rheumatol. 2014

3 GlobalData

4 Europe includes FR, DE, IT, ES, UK only



Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

PRESS RELEASE: NACON ANNOUNCES A SPECIAL EDITION THEMED REVOLUTION UNLIMITED PRO CONTROLLER FOR THE NEXT CALL OF DUTY® GAME28.9.2020 18:00:10 CESTPress release

NACON ANNOUNCES A SPECIAL EDITION THEMED REVOLUTION UNLIMITED PRO CONTROLLER FOR THE NEXT CALL OF DUTY GAME Lesquin, September 28, 2020 – NACON, a leading designer and distributor of gaming accessories, is pleased to announce it has entered into a licensing agreement with Activision to create a special edition themed REVOLUTION Unlimited Pro Controller for the next game in the iconic Call of Duty franchise. Planned for release on November 13th 2020, Call of Duty: Black Ops Cold War drops players into the depth of the Cold War’s volatile geopolitical universe in a gripping experience where nothing is as it seems. In addition to the story campaign, Black Ops Cold War will bring an arsenal of Cold War weapons and equipment into the next generation of Black Ops Multiplayer combat, and an all-new co-operative gameplay experience with Zombies. Boasting a wireless game mode, the REVOLUTION Unlimited for PlayStation4 offers exceptional performance and multiple configuration options that compet

EVS Broadcast Equipment reports update of share buyback program28.9.2020 17:45:00 CESTPress release

Publication on September 28, 2020, after market closing Regulated information – reporting share buyback EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports update of share buyback program EVS Broadcast Equipment reports that the following transactions, conducted within the framework of the share buyback program announced on May 6, 2020, took place between September 21, 2020 and September 25, 2020. DateNumber of shares acquiredAverage price (EUR)Highest price (EUR)Lowest price (EUR)Total (EUR)21/09/20205,00013.517813.6213.42 67,589 22/09/20205,00013.582413.8013.42 67,912 23/09/20203,65015.565213.7213.46 56,813 24/09/20201,97113.577013.6613.52 26,760 25/09/20204,99313.652913.7413.54 68,169 Total20,614 13.9344 13.80 13.42 287,243 As of September 25, 2020, and since the start of the buyback program, EVS has bought 252,263 shares at an average price of EUR 15,3008, representing in total EUR 3,859,819. After aforementioned transactions

CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER28.9.2020 16:20:00 CESTPress release

Complete terms and conditions can be retrieved at http://www.riksbank.se https://www.riksbank.se/sv/penningpolitik/penningpolitiska-instrument/kop-av-foretagscertifikat/ Bid procedure on 30 September 2020 Certificate:Commercial paper issued in SEK by non-financial companies with a registered office in Sweden and with a remaining maturity of up to six months on the Bid date, i.e. with the maturity date on 30 March 2021 at the latest. Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 21 September 2020.Bids:Counterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date:Wednesday 30 September 2020Bid time:0900-0930 hours (CEST) on the Bid dateRequested volume: (corresponding nominal amount)SEK 4 billion Highest permitted bid volume: (co

Sista dag för handel med BTA28.9.2020 14:30:00 CESTPressemelding

Pressmeddelande Malmö, Sverige, 28 september 2020 Sista dag för handel med BTA Sista dag för handel med Acarix AB:s (”Acarix” eller ”Bolaget”) BTA (betald tecknad aktie) är torsdag den 1 oktober 2020 och stoppdagen är måndag den 5 oktober 2020. I företrädesemissionen, som avslutades den 8 september, gav Bolaget ut 86 156 738 aktier. Företrädesemissionen tillförde Acarix cirka 56 MSEK före avdrag för kostnader relaterade till företrädesemissionen. Företrädesemissionen har nu registrerats hos Bolagsverket och sista dag för handel i Acarix BTA infaller den 1 oktober 2020. Stoppdagen är den 5 oktober 2020 och aktier beräknas finnas på respektive VP-konto eller depå den 7 oktober 2020. Genom företrädesemissionen, som nu har registrerats hos Bolagsverket, ökade antal aktier till 137 850 781 aktier och aktiekapitalet till 1 378 507,81 SEK. Rådgivare Redeye Aktiebolag var finansiell rådgivare och Baker McKenzie var legal rådgivare i samband med företrädesemissionen. Hagberg & Aneborn agerar em

Last day of trading in paid subscribed shares (Sw. BTA)28.9.2020 14:30:00 CESTPress release

Press release Malmö, Sweden September 28, 2020 Last day of trading in paid subscribed shares (Sw. BTA) Last day of trading in subscribed paid shares ("BTA") in Acarix AB ("Acarix" or the “Company") will be Thursday the 1 October 2020 and stop day will be Monday the 5 October 2020. In the rights issue, which was completed on 8 September 2020, the Company issued 86,156,738 shares. Through the rights issue, Acarix raises approx. SEK 56 million before deduction of costs related to the rights issue. The rights issue has now been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and the last day of trading in Acarix BTA will be 1 October 2020. The stop day will be 5 October 2020. Shares are estimated to be delivered to the shareholders´ securities or custodian account, respectively, on 7 October 2020. The rights issue has been registered with the Swedish Companies Registration Office, whereby the total number of shares in Acarix amount to 137,850,781 shares and the

RESULT OF SEK CREDIT OPERATION28.9.2020 11:45:00 CESTPress release

RESULT OF SEK CREDIT OPERATION 2020-09-28Auction date:2020-09-28Payment date:2020-09-28 (at 3 pm)Maturity date:2020-12-28Term:13 weeksOffered volume:UnlimitedTotal bid amount:SEK 0 billionNumber of bids0Allotment:SEK 0 billionInterest rate:Repo rate RESULT OF SEK CREDIT OPERATION 2020-09-28Auction date:2020-09-28Payment date:2020-09-28 (at 3 pm)Maturity date:2021-03-29Term:26 weeksOffered volume:UnlimitedTotal bid amount:SEK 0 billionNumber of bids0Allotment:SEK 0 billionInterest rate: Repo rate